{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-26-000020","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.986035+00:00","generated_at":"2026-05-15T01:34:25.560261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulmonx Q1 revenue falls 9% YoY to $20.6M; net loss $13.7M","bullets":["Worldwide revenue $20.6M (-9% YoY, -12% constant currency); U.S. $13.3M (-7%), international $7.3M (-12%).","Ex-China international revenue grew 22% YoY; China sales paused awaiting registration renewal.","Gross margin improved to 78% (vs 73% Q1 2025); total op. expenses $29.0M (-6% YoY).","Adjusted EBITDA loss $8.5M; net loss $13.7M ($0.33 per share) vs $14.4M ($0.36) a year ago.","FY 2026 outlook reaffirmed: revenue $90-92M, gross margin ~75%, opex $113-115M, cash burn ~$23M."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-26-000020","json":"https://secwatch.observer/filing/0001127537-26-000020.json","markdown":"https://secwatch.observer/filing/0001127537-26-000020.md","text":"https://secwatch.observer/filing/0001127537-26-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753726000020/0001127537-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753726000020/lung-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:34:25.560261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51b47d2fcb359804bf4e1885a1b2a95722bc5e96","claim":"Pulmonx Corp reported the first quarter of 2026 ended March 31, 2026 results: revenue $20.6 million, net income Net loss in the first quarter of 2026 was $13.7 million, EPS $0.33 per share. Guidance reaffirmed.","evidence_excerpt":"invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. Recent Highlights • Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basis • Delivered $13.3 million in U.S. revenue in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1127537/000112753726000020/0001127537-26-000020-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2026 ended March 31, 2026"},{"label":"Revenue","value":"$20.6 million"},{"label":"Net income","value":"Net loss in the first quarter of 2026 was $13.7 million"},{"label":"EPS","value":"$0.33 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}